Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Doubles Q2 Revenues, Trims Loss

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market Tuesday that its second-quarter revenues doubled and it trimmed its net loss on lower R&D spending.

The Northbrook, Ill.-based molecular diagnostics firm generated revenues of $402,237 for the three-month period ended June 30, compared to revenues of $194,715 for the second quarter of 2008. Its product sales increased to $242,740 from $194,715, while it also reported grant and contract revenue of $159,497, compared to no such revenues the year before.

"With the May 2009 FDA clearance of our influenza and respiratory syncytial virus (RSV) test along with the [cystic fibrosis] assay, we have expanded our test menu to four products with four more in the pipeline," Nanosphere President and CEO William Moffitt said in a statement. "These include the assay for hemochromatosis, the second generation version of the Verigene System that incorporates automated sample processing, a second generation flu and our troponin assays."

Nanosphere's net loss for the quarter was $8.4 million, or $.38 per share, down from $9.8 million, or $.44 per share, for the second quarter of 2008. Its EPS match analysts' consensus estimate for the quarter.

The company cut its R&D spending 27 percent to $4.4 million from $6 million and its SG&A spending 3 percent to 43.7 million from $3.8 million.

Nanosphere held cash and cash equivalents of $58.2 million as of the end of the quarter.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.